of medications is limited. The United States Anti-Doping Agency (USADA) 4 and World Anti-Doping Agency (WADA) 5 publish a list of banned substances for which positive test results can risk an athlete's eligibility for a minimum of one year. All S6-classified stimulants (specified and non-specified) are prohibited (Table 1) . 4, 5 Other ADHD medications have not proven to be as effective for management of ADHD as those in the S6 classification. 3 This case report presents the course of treatment and adverse effects experienced by an elite athlete who was diagnosed with and treated for ADHD.
Case Report
The patient was a 19-year-old Caucasian female NCAA Division I athlete and UCI cyclist (Union Cyclist International is the governing body for international competitive cycling). The athlete had recently been tested and diagnosed with ADHD by her primary care physician. The patient completed an Adult Self-Report Scale (ASRS) symptom checklist. The athlete's Part A score was18, and her Part B score was also 18, which was highly suggestive of ADHD. The parent completed a Conners Parent Rating Scale 6 to assess the frequency of behaviors observed by the parent, the results of which corresponded to the athlete's self-reported symptoms.
Physical Examination
Due to escalating issues with academic performance, the athlete and parent consulted the primary care physician (PCP). Issues included inability to attend, high degree of distractibility, and on-going fidgeting and restlessness in multiple environments. Examination of vital signs yielded non-remarkable results for an elite athlete. The athlete had no known allergies, and the only issue in her past medical history was anemia. Daily iron supplements of two 15-mg liquid doses of Floradix (Flora, Inc., Lynden, WA) had successfully managed the anemia. She had no history of surgery, nor was she taking any prescribed medications. Physical examination produced normal findings, and laboratory tests yielded normal results. One remarkable finding was constant movement of the lower extremities throughout the duration of the examination.
Diagnosis
There is no simple test for the diagnosis of ADHD. The diagnosis can only be made by a trained clinician after a thorough evaluation. In order to accurately detect the presence of ADHD, other possible causes for the symptoms should be ruled out (Table 2) . 7, 8, 9 Comprehensive interviewing of the patient and key individuals in the patient's life (e.g., parent, teacher, spouse) is necessary to obtain information about the patient's behaviors. In this case, the primary care physician performed a thorough examination and interview of the athlete. The results of the ASRS and Conners' Scale were also considered, which supported the diagnosis of an inattentive type of ADHD.
Treatment
Because of USADA and WADA restrictions, the primary care physician prescribed Strattera®, which is a nonstimulant medication. Strattera®, or atomoxetine, is a selective norepinephrine reuptake inhibitor, which is rapidly absorbed from the gastrointestinal tract after oral administration (averaging one to two hours to reach maximal plasma concentrations). 10 The most common adverse effects are dry mouth (21.2%), insomnia (20.8%), nausea (12.3%), decreased appetite (11.5%), constipation (10.8%), dizziness (6.3%), and sweating (5.2%). Data from clinical trials have also identified modest increase in heart rate (11 beats per minute in standing and 5 beats per minute in a supine position) 11 and elevation of systolic blood pressure (2.3 mm Hg). 12 The athlete was initially placed on an 18 mg dose for three days, 40 mg dose for three days, and then a stable daily dose of 60 mg. Initial adverse effects of the medication were nausea, extreme fatigue, and decreased appetite. The athlete was participating in two or three workouts per day for both cycling and field hockey. The mode of conditioning was extremely high-intensity interval training (i.e., approximately 85-90% of V . O 2 maximum). In addition, the athlete completed two weight training sessions per week. After several days at 60 mg of Strattera® administration, she experienced bouts of cutis ansirina (i.e., goose bumps) and chills with diaphoresis, despite her presence in an environment having an ambient temperature exceeding 90°F. The athletic trainer and the physician initially thought that the symptoms were related to dehydration. Careful attention was directed to adequate hydration before and during workouts, but the symptoms did not resolve. Subsequently, blood glucose level was assessed at various times during the workout sessions. Blood glucose level was found to be as low as 92 mg/dL and as high as 245 mg/ dL, but no clear association between the symptoms and blood glucose level was identified. Compared to previous drug-free exercise performance, an increase in heart rate of 20 to 30 beats per minute for a given level of exercise intensity (i.e., Watts) was measured by a heart rate monitor. Her symptoms were far more pronounced during morning workouts than during afternoon or evening workouts. By the second week on the 60 mg dose of Strattera®, the athlete had vomited four times during workout sessions that were previously completed at the same intensity level without difficulty. It may be difficult to distract one from a task that interests him/her, particularly tasks that are interactive or hands-on.
After almost four weeks on Strattera®, the athlete was unable to tolerate its side effects. After consultation with the physician and athletic trainer, the athlete decided to stop taking the medication. Approximately 26 hours after the cessation of Strattera® administration, the athlete completed a 25-mile bicycle race with minimal cutis ansirina, chills, or diaphoresis. The next day (approximately 49 hours after the last dose), the athlete completed a 20-mile bicycle race with no adverse effects. USADA officials and the primary care physician agreed that Strattera® was not tolerated by the athlete and that another drug class would be more appropriate.
Summary
The physiologic changes produced by atomoxetine (Strattera®) can be problematic to the performance of an elite athlete. The sympathetic demands of exercise may conflict with the drug's influence on neurologic function. For example, the "fight or flight" response that occurs with the onset of exercise increases heart rate, elevates blood glucose level, and increases blood flow to muscles. Strattera® inhibits the uptake of the stress hormone norepinephrine, which can affect the function of smooth, skeletal, and cardiac muscle. During athletic activities, norepinephrine reuptake inhibition has been found to significantly decrease performance at both moderate and high ambient temperatures. 12 A review of the literature did not identify any research reports that were specific to the use of Strattera® in athletes. Other than elevated heart rate, the medication side effects experienced by this athlete was not reported in the literature. The extreme physical demands imposed by the activities of an elite athlete may cause adverse effects when combined with some types of medication. The medication side effects reported in this case review could represent an individualized response, but other elite athletes may be susceptible to a similar response to the medication. 
